Research Article
Efficacy of SXN in the Treatment of Iron Deficiency Anemia: A Phase IV Clinical Trial
Table 1
Demographic data of studied groups.
| | Demographic data | L-SXN | M-SXN | H-SXN | P value |
| | Sex (n, %) | | | | >0.05 | | Male | 167(38.8%) | 197(13.4%) | 337(34.3%) | | | Female | 263(61.2%) | 392(66.6%) | 645(65.7%) | | | Age (n, %) | | | | >0.05 | | 6~ | 30 (7.0%) | 149 (25.3%) | 181 (18.4%) | | | 15~ | 30 (7.0%) | 40 (6.8%) | 70 (7.1%) | | | 18~ | 250 (58.1%) | 275 (46.7%) | 526 (53.6%) | | | 65~80 | 205 (20.9%) | 125 (21.2%) | 120 (27.9%) | | | Age (mean ± SD) | | | | >0.05 | | Child (<14y) | 9.20±1.98 | 9.53±2.54 | 9.58±2.63 | | | Adult (≥14y) | 48.97±18.76 | 45.09±20.02 | 46.29±28.12 | |
|
|
